Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Published:2017-01-28 Issue:2 Volume:69 Page:277-290
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Fleischmann Roy¹,van Adelsberg Janet²,Lin Yong³,Castelar-Pinheiro Geraldo da Rocha⁴,Brzezicki Jan⁵,Hrycaj Pawel⁶,Graham Neil M. H.²,van Hoogstraten Hubert³,Bauer Deborah³,Burmester Gerd R.⁷

Affiliation:

1. Metroplex Clinical Research Center and University of Texas Southwestern Medical Center; Dallas

2. Regeneron Pharmaceuticals; Tarrytown New York

3. Sanofi; Bridgewater New Jersey

4. Rio de Janeiro State University; Rio de Janeiro Brazil

5. Centrum Kliniczno-Badawcze; Elblag Poland

6. Poznań University of Medical Sciences; Poznań Poland

7. Charité University Medicine; Free University, and Humboldt University, Berlin Germany

Funder

Sanofi and Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.39944/fullpdf

Reference40 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

2. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016

3. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment;Emery;Rheumatology (Oxford),2012

4. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study;Hyrich;Arthritis Rheum,2007

5. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges;Smolen;Nat Rev Rheumatol,2015

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials;Modern Rheumatology;2024-07-29

2. The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study;Modern Rheumatology;2024-07-29

3. Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study;Expert Opinion on Drug Safety;2024-07-25

4. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

5. Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study;Modern Rheumatology;2024-05-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3